INS and myeloid sarcoma: found improvements in peripheral and hepatic insulin sensitivity six weeks after infusion of microbiota from lean donors into recipients with MS, and concluded that the gut microbiota could potentially be developed as a therapeutic agent to increase insulin sensitivity in humans (Vrieze et al., 2012).